Overcoming the dependence on animal models for osteoarthritis therapeutics–the promises and prospects of in vitro models

YP Singh, JC Moses, N Bhardwaj… - Advanced healthcare …, 2021 - Wiley Online Library
Osteoarthritis (OA) is a musculoskeletal disease characterized by progressive degeneration
of osteochondral tissues. Current treatment is restricted to the reduction of pain and loss of …

[HTML][HTML] Cartilage and bone destruction in arthritis: pathogenesis and treatment strategy: a literature review

D Tateiwa, H Yoshikawa, T Kaito - Cells, 2019 - mdpi.com
Arthritis is inflammation of the joints accompanied by osteochondral destruction. It can take
many forms, including osteoarthritis, rheumatoid arthritis, and psoriatic arthritis. These …

[HTML][HTML] Osteoarthritis: a narrative review of molecular approaches to disease management

LA Salman, G Ahmed, SG Dakin, B Kendrick… - Arthritis Research & …, 2023 - Springer
Osteoarthritis (OA) is a chronic, progressive degenerative whole joint disease that affects the
articular cartilage, subchondral bone, ligaments, capsule, and synovium. While it is still …

Inflammation and joint tissue interactions in OA: implications for potential therapeutic approaches

R Rainbow, W Ren, L Zeng - Arthritis, 2012 - Wiley Online Library
It is increasingly recognized that the pathogenesis of cartilage degradation in osteoarthritis
(OA) is multifactorial and involves the interactions between cartilage and its surrounding …

[HTML][HTML] Recent advances in understanding the phenotypes of osteoarthritis

A Mobasheri, S Saarakkala, M Finnilä… - …, 2019 - ncbi.nlm.nih.gov
Recent research in the field of osteoarthritis (OA) has focused on understanding the
underlying molecular and clinical phenotypes of the disease. This narrative review article …

[HTML][HTML] OA clinical trials: current targets and trials for OA. Choosing molecular targets: what have we learned and where we are headed?

MPH Le Graverand-Gastineau - Osteoarthritis and cartilage, 2009 - Elsevier
OBJECTIVE: The purpose of this article is to review the current status of drug development
as it relates to both molecular targets and clinical trials for osteoarthritis (OA). METHODS: A …

Osteoarthritis in 2007.

S Krasnokutsky, J Samuels… - Bulletin of the NYU …, 2007 - search.ebscohost.com
Osteoarthritis (OA) is often a progressive and disabling disease resulting from a combination
of risk factors, including age, genetics, trauma, and knee alignment, as well as an imbalance …

Stem cell-based microphysiological osteochondral system to model tissue response to interleukin-1β

H Lin, TP Lozito, PG Alexander, R Gottardi… - Molecular …, 2014 - ACS Publications
Osteoarthritis (OA) is a chronic degenerative disease of the articular joint that involves both
bone and cartilage degenerative changes. An engineered osteochondral tissue within …

Pathophysiological landscape of osteoarthritis

P Kulkarni, A Martson, R Vidya, S Chitnavis… - Advances in clinical …, 2021 - Elsevier
A sharp rise in osteoarthritis (OA) incidence is expected as over 25% of world population
ages in the coming decade. Although OA is considered a degenerative disease, mounting …

[HTML][HTML] The hallmarks of osteoarthritis and the potential to develop personalised disease-modifying pharmacological therapeutics

DP Tonge, MJ Pearson, SW Jones - Osteoarthritis and cartilage, 2014 - Elsevier
Osteoarthritis (OA) is an age-related condition and the leading cause of pain, disability and
shortening of adult working life in the UK. The incidence of OA increases with age, with 25 …